---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-062406"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:31:03.298821+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quoin Pharma receives FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

## Summary
- FDA granted Rare Pediatric Disease Designation (RPDD) on June 24, 2025 for QRX003.
- QRX003 is Quoin's lead asset for treating Netherton Syndrome, a rare genetic disorder.
- RPDD makes QRX003 eligible for priority review and a Rare Pediatric Disease Priority Review Voucher if approved.
- Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases.
- The designation underscores the unmet need in Netherton Syndrome with no approved therapies.

## SEC filing metadata
- accession: 0001104659-25-062406
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925062406/0001104659-25-062406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925062406/tm2518927d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-062406
- JSON: https://secwatch.observer/filing/0001104659-25-062406.json
- Plain text: https://secwatch.observer/filing/0001104659-25-062406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.